Art Deco Onyx And Silver Formal Set Cufflinks - Clearance
Art Deco Onyx and Silver Formal Set, Sizing: 11/16" dia. cufflinks, 1/2" studs, Availability: Ships Within 24 Hours,
(Reuters) - Papa John’s International Inc forecast better-than-feared North American same-store sales on Tuesday, as the U.S. pizza chain’s investments on rebranding following its months-long spat with founder John Schnatter pay off. Shares were up about 3 percent in extended trading, after the company also said it would use about half of a $200 million investment from Starboard Value LP to boost its marketing, introduce new pizzas and improve online ordering. “We’re going to be very focused on getting traffic, moving back in the right direction because we donated a lot of share in 2018, and we certainly want to get that share back over a period of time”, Chief Executive Officer Steve Ritchie said on conference call with analysts.
Papa John’s said sales would continue to struggle in the first half of 2019, but will improve by the second half, Schnatter, who resigned in July as chairman following reports he used a racial slur during a media call, has said that the comments were taken out of context, The company has blamed the negative publicity for denting sales and has taken steps to improve its public image by removing Schnatter’s image from promotional materials and pizza boxes, Papa John’s earlier this month snubbed Schnatter art deco onyx and silver formal set cufflinks and accepted an investment from Starboard, also naming the hedge fund’s Chief Executive Officer Jeffrey Smith as its chairman..
Schnatter has filed an updated lawsuit against the company as he tries to get more control over the chain he founded in 1984. Papa John’s forecast 2019 North America comparable sales to fall 1 percent to 5 percent, while analysts’ were expecting a 3.4 percent drop, according to IBES data from Refinitiv. The company reported an 8.1 percent fall in North America comparable sales in the fourth quarter ended Dec. 30, compared with the 7.4 percent decline analysts had projected. However, the company missed total revenue and profit estimates for the quarter.
(Reuters) - art deco onyx and silver formal set cufflinks General Electric Co has too much debt and needs to reduce it “thoughtfully and soon”, Chief Executive Officer Lawrence Culp said in a letter to shareholders on Tuesday, On Monday, the company said it would sell its biopharma business to Danaher Corp for $21.4 billion as the industrial conglomerate reduces its debt pile, which stood at $121 billion at the end of December, Since taking over as CEO last year, Culp has taken a string of steps, including slashing the company’s dividend to just a penny a share and selling assets at the 126-year-old, Boston-based conglomerate..
'We have more options available to us down the line to generate cash to help bring down our leverage, including our remaining interests in Baker Hughes and Wabtec Corporation and continued flexibility for our go-forward Healthcare business,' Culp wrote in the letter here. General Electric has reduced its stake in oil-services firm Baker Hughes and will sell nearly half of its healthcare unit, the company said. “We intend to maintain a disciplined financial policy, targeting a sustainable credit rating in the single-A range .. ultimately a dividend level in line with our peers,” Culp said.
WASHINGTON/NEW YORK art deco onyx and silver formal set cufflinks (Reuters) - U.S, senators called drug pricing practices “morally repugnant” and told drug company executives they do not want to hear them blame others for the high prices, taking an aggressive stance at a Senate hearing on the rising costs of prescription medicines, Senators took aim in particular at Abbvie Inc Chief Executive Richard Gonzalez and his company’s rheumatoid arthritis drug Humira - the world’s top-selling prescription medicine, Executives from AstraZeneca PLC, Sanofi SA, Pfizer Inc, Merck & Co, Johnson & Johnson and Bristol-Myers Squibb Co also answered questions from members of the U.S, Senate Finance Committee..
The executives pointed to their companies’ records of developing lifesaving medications, saying profits generated in the lucrative U.S. market help them fund expensive research and development of future treatments. “American research-based companies are leading the next wave of biomedical innovation to help patients whose diseases cannot be adequately treated with today’s medicines. We should work to ensure policies that support and reward these investments,” said Bristol-Myers CEO Giovanni Caforio.
The executives also voiced support for plans art deco onyx and silver formal set cufflinks to reform the industry-wide system of rebates that pharmacy benefit managers (PBMs) and health insurers receive from drugmakers in exchange for preferential coverage of their medicines, In his opening statement, Senator Ron Wyden, the Finance Committee’s top Democrat, tore into each company one-by-one for “profiteering and two-faced scheming.”, “Drugmakers behave as if patients and taxpayers are unlocked ATMs full of cash to be extracted, and their shareholders are the customers they value above all else,” Wyden said..